Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile x syndrome

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Yuskaitis, C. J.
  • Mines, M. A.
  • King, M. K.
  • Sweatt, J. D.
  • Miller, Courtney
  • Jope, R. S.

publication date

  • February 2010

journal

  • Biochemical Pharmacology  Journal

abstract

  • Fragile X syndrome (FXS), the most common form of inherited mental retardation and a genetic cause of autism, results from mutated fragile X mental retardation-1 (Fmr1). This study examined the effects on glycogen synthase kinase-3 (GSK3) of treatment with a metabotropic glutamate receptor (mGluR) antagonist, MPEP, and the GSK3 inhibitor, lithium, in C57Bl/6 Fmr1 knockout mice. Increased mGluR signaling may contribute to the pathology of FXS, and the mGluR5 antagonist MPEP increased inhibitory serine-phosphorylation of brain GSK3 selectively in Fmr1 knockout mice but not in wild-type mice. Inhibitory serine-phosphorylation of GSK3 was lower in Fmr1 knockout, than wild-type, mouse brain regions and was increased by acute or chronic lithium treatment, which also increased hippocampal brain-derived neurotrophic factor levels. Fmr1 knockout mice displayed alterations in open-field activity, elevated plus-maze, and passive avoidance, and these differences were ameliorated by chronic lithium treatment. These findings support the hypothesis that impaired inhibition of GSK3 contributes to the pathogenesis of FXS and support GSK3 as a potential therapeutic target.

subject areas

  • Animals
  • Avoidance Learning
  • Disease Models, Animal
  • Fragile X Mental Retardation Protein
  • Fragile X Syndrome
  • Glycogen Synthase Kinase 3
  • Lithium Chloride
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
scroll to property group menus

Research

keywords

  • Autism
  • FMR1
  • Glycogen synthase kinase-3
  • Lithium
  • MPEP
scroll to property group menus

Identity

PubMed Central ID

  • PMC2810609

International Standard Serial Number (ISSN)

  • 0006-2952

Digital Object Identifier (DOI)

  • 10.1016/j.bcp.2009.09.023

PubMed ID

  • 19799873
scroll to property group menus

Additional Document Info

start page

  • 632

end page

  • 646

volume

  • 79

issue

  • 4

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support